Loading…
PETHIDINE HYDROCHLORIDE is a brand name for Meperidine (also known as Pethidine). The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: 1) Obstetric analgesia. 2) Moderate to severe pain. 3) Premedication and analgesia during anaesthesia.
Verbatim from this product's MHRA label. Tap a section to expand.
Posology Adults:
The normal single dose, usually not to be repeated more often than four hourly, is as follows: Orally: 50 - 150 mg. Elderly and debilitated patients The initial dose should not exceed 50 mg orally as such patients are likely to be particularly sensitive to the central depressant effects of the drug.
5 - 2 mg / kg body weight orally. This dose may be repeated if clinically necessary but it should not be repeated more often than four hourly. 4). Method of Administration For oral administration.
4) Nervous system disorders Unknown Central Nervous System excitation, dizziness, vertigo, drowsiness, headache Eye disorders Unknown Obtund or abolish the corneal reflex, miosis (pupillary constriction) Cardiac disorders Unknown Bradycardia, tachycardia, palpitations Vascular disorders Unknown Hypotension, facial flushing, Respiratory, thoracic and mediastinal disorders Unknown Respiratory depression Gastrointestinal disorders Unknown Nausea,vomiting, constipation, dry mouth Hepatobiliary disorders Unknown Biliary spasm Skin and subcutaneous tissue disorders Unknown Rashes, urticaria, pruritis Musculoskeletal and connective tissue disorders Unknown Muscle rigidity Renal and urinary disorders Unknown Difficulty in micturition, ureteral spasm Reproductive system and breast disorders Unknown Decreased libido or potency General disorders and administration site conditions Unknown Sweating , hypothermia Uncommon Drug withdrawal syndrome Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard) or search for MHRA Yellow Card in the Google Play or Apple App Store.
Paediatric population Pethidine has a slower elimination rate and a larger inter-subject variability in neonates and young infants compared to older children and adults, which may lead to dose related reactions such as respiratory depression.
If pethidine use is contemplated in neonates or young infants (up to 12 months), any potential benefits of the drug need to be weighed against the relative risk to the patient. Drug dependence, tolerance and potential for abuse For all patients, prolonged use of this product may lead to drug dependence (addiction), even at therapeutic doses.
, major depression). Additional support and monitoring may be necessary when prescribing for patients at risk of opioid misuse. A comprehensive patient history should be taken to document concomitant medications, including over-the-counter medicines and medicines obtained on- line, and past and present medical and psychiatric conditions.
Patients may find that treatment is less effective with chronic use and express a need to increase the dose to obtain the same level of pain control as initially experienced. Patients may also supplement their treatment with additional pain relievers.
These could be signs that the patient is developing tolerance. The risks of developing tolerance should be explained to the patient. Overuse or misuse may result in overdose and/or death. It is important that patients only use medicines that are prescribed for them at the dose they have been prescribed and do not give this medicine to anyone else.
Patients should be closely monitored for signs of misuse, abuse, or addiction. The clinical need for analgesic treatment should be reviewed regularly. Drug withdrawal syndrome Prior to starting treatment with any opioids, a discussion should be held with patients to put in place a withdrawal strategy for ending treatment with pethidine hydrochloride.
1. Not to be given to comatose patients or to patients with respiratory depression, obstructive airways disease or acute asthma. It should not be given to patients who are receiving monoamine oxidase inhibitors or moclobemide, or within two weeks of their withdrawal.
For full list of interactions with other medicinal products, see section
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Meperidine in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Drug withdrawal syndrome may occur upon abrupt cessation of therapy or dose reduction. When a patient no longer requires therapy, it is advisable to taper the dose gradually to minimise symptoms of withdrawal. Tapering from a high dose may take weeks to months.
The opioid drug withdrawal syndrome is characterised by some or all of the following: restlessness, lacrimation, rhinorrhoea, yawning, perspiration, chills, myalgia, mydriasis and palpitations. Other symptoms may also develop including irritability, agitation, anxiety, hyperkinesia, tremor, weakness, insomnia, anorexia, abdominal cramps, nausea, vomiting, diarrhoea, increased blood pressure, increased respiratory rate or heart rate.
If women take this drug during pregnancy, there is a risk that their newborn infants will experience neonatal withdrawal syndrome. Hyperalgesia Hyperalgesia may be diagnosed if the patient on long-term opioid therapy presents with increased pain.
This might be qualitatively and anatomically distinct from pain related to disease progression or to breakthrough pain resulting from development of opioid tolerance. Pain associated with hyperalgesia tends to be more diffuse than the pre-existing pain and less defined in quality.
Symptoms of hyperalgesia may resolve with a reduction of opioid dose. Pethidine hydrochloride should only be given with caution, and in reduced dosage, to neonates and premature infants, elderly or debilitated patients, hypotension, decreased respiratory reserve, biliary tract disorders, hypothyroidism, adrenal cortical insufficiency, shock, prostatic hypertrophy, and supraventricular tachycardia.
Use of cough suppressants containing opioid analgesics is not generally recommended in children and should be avoided altogether in those under at least 1 year. Cross tolerance between narcotic analgesics can occur. In the case of severe continuing pain it may be advisable to try other treatments.
A reduction in dose is advisable in cases of renal disease and chronic hepatic disease. Pethidine hydrochloride tablets contain lactose monohydrate and sucrose. Patients with rare hereditary problems of galactose intolerance, fructose intolerance, the Lapp lactase deficiency, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
Risk from concomitant use of sedative medicines such as benzodiazepines or related drugs Concomitant use of pethidine and sedative medicines such as benzodiazepines or related drugs may result in sedation, respiratory depression, coma and death.
Because of these risks, concomitant prescribing with these sedative medicines should be reserved for patients for whom alternative treatment options are not possible. If a decision is made to prescribe pethidine concomitantly with sedative medicines, the lowest effective dose should be used, and the duration of treatment should be as short as possible.
The patients should be followed closely for signs and symptoms of respiratory depression and sedation. In this respect, it is strongly recommended to inform patients and their caregivers to be aware of these symptoms (see section “Interaction with other medicinal products and other forms of interaction”).
5).